Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026
A broad-spectrum inhibitor of copper-exporting P<sub>1B</sub>-type ATPases.
These findings establish a conserved, druggable vulnerability in Cu<sup>+</sup>-ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
TL;DR
These findings establish a conserved, druggable vulnerability in Cu<sup>+</sup>-ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
Key findings
- We further identified a single charged P-domain residue that governed MKV3 affinity and potency across species.
- Functionally, MKV3 phenocopied the genetic loss of Cu<sup>+</sup>-ATPases in bacteria, fungi, plants, zebrafish, and mammals, impairing copper-dependent enzymes, transporter trafficking, and copper tolerance.
- These findings establish a conserved, druggable vulnerability in Cu<sup>+</sup>-ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
What they did
In silico docking against the <i><i>Xenopus</i></i> ATP7B structure revealed a highly conserved pocket suitable for pharmacological inhibition. MKV3 bound human ATP7A and ATP7B with nanomolar affinity, competed with N-terminal metal-binding domains for access to the Cu<sup>+</sup> entry site, and selectively inhibited <i><i>Escherichia coli</i></i> CopA ATPase activity and Cu<sup>+</sup> transport. Mechanistically, MKV3 blocked chaperone-mediated Cu<sup>+</sup> delivery to the intramembranous CPC site of CopA that is essential for its transport function.
Full abstract (original)
Background: Copper (Cu) transporting ATPases represent a highly conserved subclass of P-type ATPases with critical roles in Cu export and metalloenzyme synthesis. Despite their important biological roles and association with a wide range of human diseases, no high-affinity small-molecule inhibitors have been described. Here, we identify MKV3 as a small molecule inhibitor of Cu-transporting P-type ATPases that targets a conserved Cu<sup>+</sup> entry site to the translocation pathway.
What they did: In silico docking against the <i><i>Xenopus</i></i> ATP7B structure revealed a highly conserved pocket suitable for pharmacological inhibition. MKV3 bound human ATP7A and ATP7B with nanomolar affinity, competed with N-terminal metal-binding domains for access to the Cu<sup>+</sup> entry site, and selectively inhibited <i><i>Escherichia coli</i></i> CopA ATPase activity and Cu<sup>+</sup> transport. Mechanistically, MKV3 blocked chaperone-mediated Cu<sup>+</sup> delivery to the intramembranous CPC site of CopA that is essential for its transport function.
Results & conclusions: We further identified a single charged P-domain residue that governed MKV3 affinity and potency across species. Functionally, MKV3 phenocopied the genetic loss of Cu<sup>+</sup>-ATPases in bacteria, fungi, plants, zebrafish, and mammals, impairing copper-dependent enzymes, transporter trafficking, and copper tolerance. These findings establish a conserved, druggable vulnerability in Cu<sup>+</sup>-ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2604078123 · PubMed 42133807.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Proceedings of the National Academy of Sciences (PNAS) study find?
These findings establish a conserved, druggable vulnerability in Cu<sup>+</sup>-ATPases and introduce MKV3 as a broadly active chemical tool to modulate copper homeostasis across biological kingdoms.
What type of study is this?
It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. In silico docking against the <i><i>Xenopus</i></i> ATP7B structure revealed a highly conserved pocket suitable for pharmacological inhibition.
Where can I read the original paper?
The original is at the publisher via DOI 10.1073/pnas.2604078123. PubMed ID: 42133807. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-broad-spectrum-inhibitor-of-copper-exporting-p-lt-sub-gt-1b-lt-sub-gt-078123/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides